ME03815B - Kristalni oblici modulatora receptora androgena - Google Patents

Kristalni oblici modulatora receptora androgena

Info

Publication number
ME03815B
ME03815B MEP-2020-163A MEP2020163A ME03815B ME 03815 B ME03815 B ME 03815B ME P2020163 A MEP2020163 A ME P2020163A ME 03815 B ME03815 B ME 03815B
Authority
ME
Montenegro
Prior art keywords
crystalline form
theta
pharmaceutical composition
crystal
crystalline
Prior art date
Application number
MEP-2020-163A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Anna Dilhas
Ouathek Ouerfelli
Nicholas D Smith
Mark R Herbert
Original Assignee
Sloan Kettering Inst Cancer Res
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03815(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer Res, Aragon Pharmaceuticals Inc filed Critical Sloan Kettering Inst Cancer Res
Publication of ME03815B publication Critical patent/ME03815B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MEP-2020-163A 2012-06-07 2013-06-04 Kristalni oblici modulatora receptora androgena ME03815B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
EP18157435.1A EP3348553B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
ME03815B true ME03815B (me) 2021-04-20

Family

ID=49712550

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2020-163A ME03815B (me) 2012-06-07 2013-06-04 Kristalni oblici modulatora receptora androgena
MEP-2018-158A ME03081B (me) 2012-06-07 2013-06-04 Modulatora receptora androgena patentni zahtevi

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2018-158A ME03081B (me) 2012-06-07 2013-06-04 Modulatora receptora androgena patentni zahtevi

Country Status (45)

Country Link
US (9) US9481663B2 (und)
EP (4) EP3533792B1 (und)
JP (3) JP6182209B2 (und)
KR (2) KR102062024B1 (und)
CN (3) CN113135892A (und)
AU (3) AU2013271751B2 (und)
BR (1) BR112014030678A2 (und)
CA (4) CA3008345C (und)
CL (1) CL2014003331A1 (und)
CO (1) CO7240407A2 (und)
CR (2) CR20190331A (und)
CY (4) CY1120393T1 (und)
DK (3) DK3348553T3 (und)
EA (3) EA033956B1 (und)
EC (1) ECSP14030098A (und)
ES (3) ES2809738T3 (und)
FR (1) FR21C1050I2 (und)
GT (1) GT201400283A (und)
HK (2) HK1210175A1 (und)
HR (3) HRP20180902T1 (und)
HU (4) HUE054595T2 (und)
IL (5) IL267608B1 (und)
IN (1) IN2014DN10084A (und)
LT (4) LT3348553T (und)
LU (1) LUC00236I2 (und)
ME (2) ME03815B (und)
MX (1) MX356754B (und)
MY (1) MY187500A (und)
NI (1) NI201400142A (und)
NL (1) NL301144I2 (und)
NO (1) NO2021046I1 (und)
NZ (2) NZ717683A (und)
PE (3) PE20150631A1 (und)
PH (2) PH12014502714A1 (und)
PL (3) PL3533792T3 (und)
PT (3) PT2858985T (und)
RS (3) RS61988B1 (und)
SG (3) SG10201610249TA (und)
SI (3) SI2858985T1 (und)
SM (3) SMT202100355T1 (und)
TR (1) TR201808939T4 (und)
TW (1) TWI532732B (und)
UA (2) UA123142C2 (und)
WO (1) WO2013184681A1 (und)
ZA (1) ZA201500076B (und)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
US9018244B2 (en) 2011-12-16 2015-04-28 Olema Pharmaceuticals, Inc. Benzopyran compounds, compositions and uses thereof
PE20150631A1 (es) 2012-06-07 2015-05-11 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador del receptor androgenico
CA2884795C (en) 2012-09-11 2023-10-17 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP3186247B1 (en) * 2014-08-26 2021-03-03 Astar Biotech LLC Protein kinase inhibitors
AU2015358490B2 (en) 2014-12-05 2021-04-08 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41111B1 (fr) 2014-12-05 2021-09-30 Aragon Pharmaceuticals Inc Compositions anticancéreuses
EP3842034B1 (en) 2014-12-05 2025-02-12 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3235345B1 (en) 2014-12-19 2024-03-06 Lutron Technology Company LLC Multi-channel lighting fixture having multiple light-emitting diode drivers
JP2019517497A (ja) 2016-06-03 2019-06-24 アラゴン ファーマシューティカルズ，インコーポレイテッド 抗癌性組成物
US11149017B2 (en) 2016-12-13 2021-10-19 Watson Laboratories Inc. Solid state forms of apalutamide
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
CA3104026A1 (en) * 2018-06-20 2019-12-26 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of arn-509, preparation method therefor and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) * 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
WO2021033098A1 (en) * 2019-08-22 2021-02-25 Dr. Reddy’S Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4208451A1 (en) 2020-09-04 2023-07-12 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
DK2656841T3 (en) 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
MX2008012492A (es) * 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2536708A4 (en) * 2010-02-16 2013-05-29 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
PE20150631A1 (es) 2012-06-07 2015-05-11 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador del receptor androgenico
CA3104026A1 (en) 2018-06-20 2019-12-26 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of arn-509, preparation method therefor and use thereof

Also Published As

Publication number Publication date
JP2017178923A (ja) 2017-10-05
HUE038082T2 (hu) 2018-09-28
IL320522A (en) 2025-06-01
PE20150631A1 (es) 2015-05-11
KR102195916B1 (ko) 2020-12-30
PT3348553T (pt) 2020-09-28
PH12016501470A1 (en) 2017-07-10
LT2858985T (lt) 2018-09-25
KR20190132543A (ko) 2019-11-27
CN105693692A (zh) 2016-06-22
IL267608B1 (en) 2025-06-01
MX356754B (es) 2018-06-11
GT201400283A (es) 2017-07-03
US10308630B2 (en) 2019-06-04
US9994545B2 (en) 2018-06-12
HUE050357T2 (hu) 2020-11-30
US20150133481A1 (en) 2015-05-14
US10766875B2 (en) 2020-09-08
KR20150021993A (ko) 2015-03-03
HRP20201387T1 (hr) 2020-11-27
PL2858985T3 (pl) 2018-09-28
US20210163441A1 (en) 2021-06-03
AU2013271751B2 (en) 2017-02-23
CA3008345C (en) 2019-10-22
EA201992010A1 (ru) 2020-01-24
MX2014015005A (es) 2015-09-04
RS61988B1 (sr) 2021-07-30
ES2875932T3 (es) 2021-11-11
CR20190331A (es) 2019-11-12
AU2017200298A1 (en) 2017-02-02
NO2021046I1 (no) 2021-11-02
NZ702203A (en) 2016-09-30
ES2670683T3 (es) 2018-05-31
HUS2100047I1 (hu) 2021-11-29
HUE054595T2 (hu) 2021-09-28
RS60617B1 (sr) 2020-09-30
EA033956B1 (ru) 2019-12-13
CY1124831T1 (el) 2022-03-24
PH12016501470B1 (en) 2021-12-10
FR21C1050I2 (fr) 2024-05-24
CA2875767A1 (en) 2013-12-12
SMT202100355T1 (it) 2021-07-12
SMT201800311T1 (it) 2018-07-17
PL3533792T3 (pl) 2021-11-29
HK1226066A1 (zh) 2017-09-22
LTPA2021525I1 (und) 2021-11-25
PH12014502714B1 (en) 2015-02-02
CR20140549A (es) 2015-04-06
CY2021032I2 (el) 2022-03-24
IL236055A0 (en) 2015-02-01
SG11201408140QA (en) 2015-01-29
ME03081B (me) 2019-01-20
CA3114726A1 (en) 2013-12-12
AU2013271751A1 (en) 2014-12-18
RS57370B1 (sr) 2018-08-31
SMT202000496T1 (it) 2020-11-10
DK2858985T3 (en) 2018-05-28
IL259738A (en) 2018-07-31
CA2875767C (en) 2018-08-14
LT3533792T (lt) 2021-07-26
TWI532732B (zh) 2016-05-11
ECSP14030098A (es) 2016-01-29
EP2858985A1 (en) 2015-04-15
FR21C1050I1 (fr) 2021-12-10
EP2858985A4 (en) 2016-05-25
US20170001977A1 (en) 2017-01-05
MY187500A (en) 2021-09-24
AU2017200298B2 (en) 2017-09-28
CA3055660A1 (en) 2013-12-12
US20250092011A1 (en) 2025-03-20
EA028791B1 (ru) 2017-12-29
EP3348553B1 (en) 2020-07-08
US10526310B2 (en) 2020-01-07
US9481663B2 (en) 2016-11-01
US20180258067A1 (en) 2018-09-13
CN104619692A (zh) 2015-05-13
IL267608A (en) 2019-08-29
WO2013184681A1 (en) 2013-12-12
AU2017279807B2 (en) 2018-11-08
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
CO7240407A2 (es) 2015-04-17
SI3533792T1 (sl) 2021-11-30
JP6345821B2 (ja) 2018-06-20
EP3533792B1 (en) 2021-05-05
IN2014DN10084A (und) 2015-08-21
KR102062024B1 (ko) 2020-01-03
EP3348553A1 (en) 2018-07-18
CL2014003331A1 (es) 2016-03-04
ES2809738T3 (es) 2021-03-05
UA123142C2 (uk) 2021-02-24
PH12014502714A1 (en) 2015-02-02
SI2858985T1 (sl) 2018-12-31
US20200115361A1 (en) 2020-04-16
DK3348553T3 (da) 2020-07-27
NZ717683A (en) 2018-04-27
CA3008345A1 (en) 2013-12-12
HK1210175A1 (en) 2016-04-15
EP3533792A1 (en) 2019-09-04
PE20200795A1 (es) 2020-08-10
IL275413A (en) 2020-07-30
TW201402561A (zh) 2014-01-16
CY2021032I1 (und) 2022-03-24
JP2018141009A (ja) 2018-09-13
US20200354335A1 (en) 2020-11-12
JP6182209B2 (ja) 2017-08-16
US20190241539A1 (en) 2019-08-08
TR201808939T4 (tr) 2018-07-23
SI3348553T1 (sl) 2020-11-30
UA115665C2 (uk) 2017-12-11
CY1123427T1 (el) 2021-12-31
ZA201500076B (en) 2016-10-26
PT2858985T (pt) 2018-07-10
BR112014030678A2 (pt) 2017-06-27
PT3533792T (pt) 2021-06-07
PE20200725A1 (es) 2020-07-21
CY1120393T1 (el) 2019-07-10
LT3348553T (lt) 2020-09-25
US20190330182A1 (en) 2019-10-31
SG10201610249TA (en) 2017-02-27
CN113135892A (zh) 2021-07-20
EA201492272A1 (ru) 2015-05-29
US10556882B2 (en) 2020-02-11
PL3348553T3 (pl) 2021-02-08
IL259738B (en) 2021-06-30
EA201791592A1 (ru) 2018-01-31
HRP20210909T1 (hr) 2021-09-03
LUC00236I2 (und) 2025-02-03
JP2015518890A (ja) 2015-07-06
SG10201610248SA (en) 2017-02-27
US12018008B2 (en) 2024-06-25
DK3533792T3 (da) 2021-06-28
AU2017279807A1 (en) 2018-01-25
EP3922629A1 (en) 2021-12-15
NL301144I2 (nl) 2025-03-20
EP2858985B1 (en) 2018-04-18
HRP20180902T1 (hr) 2018-08-24

Similar Documents

Publication Publication Date Title
ME03815B (me) Kristalni oblici modulatora receptora androgena
IL258732A (en) Salts and their benzene and polymorphs
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MX2012012328A (es) Compuestos pirazol como inhibidores de jak.
EP3363797A8 (en) Oral dosage form of apoptosis signal-regulating kinase inhibitors
CA2798675A1 (en) Polymorphs of 2'-o-fucosyllactose and producing thereof
SG10201407504YA (en) Pharmaceutical compositions comprising sigma receptor ligands
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
CL2012001699A1 (es) Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras.
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
FI3057962T3 (fi) Hydrokloridisuolamuoto ezh2-estoon
RU2010152758A (ru) Кристаллическая форма и тозилат соединения тетрациклина, кристаллическая форма указанного тозилата и ее полиморфная модификация, способ получения тозилата соединения тетрациклина, полиморфная модификация, полученная указанным способом, и фармацевтические композиции на основе вышеуказанных кристаллической формы и полиморфной модификации
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
JP2008540367A5 (und)
MX2013007909A (es) Formulaciones inmunosupresoras.
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
MX2011007267A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
PH12022551523A1 (en) Cyclic compounds and methods of using same
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
MX343234B (es) Formas cristalinas de 6-(1h-imidazol-1-il)-2-fenilquinazolina.
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
MX369738B (es) Formas cristalinas de sales de n-(4-((3-(2-amino-4-pirimidinil)-2- piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas.